PD04-01: ALDH1L1 Overexpression Promotes Tumor Progression and Angiogenesis and Serves as a Predictor of Poor Prognosis in Urothelial Carcinoma

PD04-02: The Contribution of MRE11, RAD50, and NBS1 Genotypes to Bladder Cancer Susceptibility in mid-Taiwan

PD04-03: Urine biomarkers enables the detection of urothelial carcinoma

PD04-04: Urinary Extracellular Vesicles as Non-Invasive Liquid Biopsies for Predicting Metastasis in Upper Tract Urothelial Carcinoma

PD04-05: Real-World Efficacy and Safety of Neoadjuvant Enfortumab Vedotin plus Pembrolizumab in High-Risk Bladder and Upper Tract Urothelial Carcinoma

PD04-06: Validation of the Neoadjuvant Chemotherapy Vesical Imaging-Reporting and Data System (nacVI-RADS) in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Enfortumab Vedotin and Pembrolizumab